Accedi a banche dati online | Convegnodetail
Anteprima di stampa
 
 

3rd Annual RAS Targeted Drug Development Summit!

Evvnt Promotion / evvnt
-
21.09.2021 - 23.09.2021  Online
Time: 8:00 am - 5:15 pm
 
Temi della conferenza
As promising clinical trial data emerges for KRAS G12C inhibitors and with strong chances of receiving FDA approval this year, the once undruggable RAS family of proteins no longer seem impossible to be cracked. This has undoubtedly resulted in great momentum in the field of oncology to develop RAS targeted therapies that safely, effectively and selectively drug all RAS driven cancers beyond those caused by G12C mutation.
Professional congress organizer (PCO)
Hanson Wade
Annotazioni
Brochure: https://go.evvnt.com/790905-3?pid=4832

Speakers: Gregory Friberg, Vice President Global Development and Oncology Therapeutic Area Head, Amgen, Susan Yang, Adagrasib Medical Lead, Mirati Therapeutics and more
 

Informazioni ed Iscrizioni:

https://go.evvnt.com/790905-0?pid=4832
Mr. Customer Service
 
Categorie
Medicina General
Lingua
Inglese
Quote del Congresso
USD 2099.00 - USD 4198.00
I partecipanti attesi
1000
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."

Centro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioHilfswerk AustriaEuropean Health Forum GasteinCenter of ExcellenceAnästhesie in Entwicklungsländern e. V.OÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation Alumni Club Medizinische Universität WienCharité International Academy